STATERA BIOPHARMA INC

STAB | USA Pink Sheets

Business Summary

Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis. Through its developmental Advanced Immunomodulating Multi-Component System (AIMS) platform, it has advanced several late-stage developmental product candidates. AIMS allows it to integrate multiple factors that define a superior composition, including key pharmacokinetic-pharmacodynamic relationships, potency, and selectivity. The Company has a platform of toll-like receptor (TLR) agonists with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and Entalasta. It has clinical and preclinical programs for Crohn’s disease (STAT-201), hematology (Entolimod) and inflammation (STAT-300) in addition to potential expansion into fibromyalgia and multiple sclerosis.

Country of Incorporation

United States of America

Incorporation Date

2003-06-05

Business Sector

Pharmaceuticals & Medical Research

Company Address

2537 Research Boulevard, Suite 201

Get access to the below data and more business development tools by signing up for the MENA Company Data product.

- Ownership details

- Corporate structure

- Business classification

- Officers & Directors contact details

- Full company contact details

Find out more

Multiply your reach by contributing your content to LSEG

LSEG contributed content reaches tens of thousands of buy and sell side professionals around the world through an integrated suite of market intelligence and transaction platforms.

Find out more